Cal­i­for­nia up­start Xyphos wants to tack­le CAR-T's big prob­lems

A San Fran­cis­co biotech that’s been de­vel­op­ing an­tibi­otics for the past decade has spun out a new on­col­o­gy start­up that bor­rows ideas from ex­ist­ing CAR-T and an­ti­body ther­a­pies — and com­bines them.

That’s ac­cord­ing to the start­up’s founder and CEO Jim Knighton. The new spin­out, called Xyphos, con­sid­ers its tech “sec­ond gen­er­a­tion CAR-T” as it ad­dress­es many of the field’s no­to­ri­ous chal­lenges (in an­i­mal mod­els, at least).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER